Sector News

Valeant starts $500M in Salix cost-cutting with 250 layoffs

April 7, 2015
Life sciences
After closing its deal for Salix Pharmaceuticals, Valeant wasted no time getting down to business with the cost-cutting it’s known for. And now, North Carolina’s Triangle area has another 250-plus pharma layoffs to add to a growing list.
 
Valeant will send 258 Salix staffers packing, the Triangle Business Journal reports–an announcement that came one day after the companies officially tied the knot. The job-shedding will begin this week and carry on through Oct. 30, with the cuts hitting a wide range of job functions.
 
One area that’s safe, though, is specialty sales. After signing their original pact in February–a $10 billion offer that the Canadian pharma upped to $15.8 billion after pressure from rival bidder Endo–Valeant CEO J. Michael Pearson acknowledged that he’d need that award-winning sales force and Salix’s hospital, key account and field reimbursement teams to help his company foray into the GI arena.
 
“We believe Salix’s sales force is, by far, the strongest in the GI space and it has been a key part of their success,” he told investors on a conference call, noting later that, “we believe these customer-facing roles have played and will play a huge role in the success of the company.”
 
The layoffs are part of a cost-savings drive that will top $500 million if Pearson gets his way. As Evercore ISI analyst Umer Raffat pointed out in a February note to clients, that equates to about 75% of Salix’s SG&A and R&D expenses. But that kind of penny-pinching is par for the course for Valeant, whose business model relies on wringing money out of plentiful acquisitions. Last month, it did the same at Dendreon, chopping 77 positions from the bankrupt oncology outfit it picked up shortly before Salix.
 
Meanwhile, though, it’s a tough time to be a Triangle pharma staffer, the TBJ points out. More than 1,000 industry employees have recently been dismissed, thanks to Hospira–which Pfizer agreed to buy up earlier this year–and GlaxoSmithKline, which is wielding the ax to compensate for lost sales of fading blockbuster Advair.
 
By Carly Helfand
 

comments closed

Related News

November 27, 2022

DSM-Firmenich nutrition and beauty mega-merger edges closer as companies announce Exchange Offer

Life sciences

The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.

November 27, 2022

Merck agrees to acquire Imago for $1.35bn

Life sciences

Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.

November 27, 2022

Novo Nordisk expands API capacity

Life sciences

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.